According to a preliminary research in Israel, a fourth dose of Covid vaccination boosts antibodies to even greater levels than the third dose, but it is insufficient to prevent Omicron infections.
Within two years, Moderna hopes to produce a single booster vaccine that protects against both Covid-19 and flu, according to its CEO, who also said that data for an Omicron-specific vaccine would most likely be ready in March.
While the coronavirus will continue to spread for many years, Pfizer's chief executive, Albert Bourla, has said that this current wave should be the last to need limitations.
In comparison to the fourth quarter of 2019, the International Labor Organization reduced its employment projection, anticipating a global deficit of 52 million full-time jobs in 2022. According to the ILO, worldwide unemployment will continue above pre-pandemic levels until at least 2023.
Regev-Yochay said at a virtual press conference that giving the fourth vaccine to the most vulnerable was the right decision because it may have provided additional protection against omicron. However, she emphasized that the findings did not justify a broader deployment to the whole population.
Sheba researchers are also testing a fourth dosage of the Moderna vaccine on 120 participants who have already gotten three doses of the Pfizer-BioNTech vaccine. According to Regev-Yochay, one week into the experiment, they discovered a comparable increase in antibodies to individuals who had received four Pfizer doses.
The Geneva-based group warned Monday that the uncertainty produced by Covid-19 variations is still weighing on the employment market, especially in low- and lower-middle-income nations.